Arvinas Inc

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cinemark Holdings

Carvana

Livent Corp

Plug Power

After closing lower last week, the S&P 500 and Nasdaq closed at record highs on Tuesday, before opening flat to higher on Wednesday morning. Find opportunities in today's market with the best short plays from Q.ai's deep learning algorithms.

Cinemark Holdings Inc Among Today's Top Shorts As Indices Trade Flat

Blink Charging

MGM Resorts

The Dow Jones ticked down 14 points, the S&P 500 was flat, and the Nasdaq rose about 0.2%. Find opportunities in today's market with the best short plays from Q.ai's artificial inteligence.

Arvinas Inc Ranked Among Today's Top Shorts Amid Pandemic-Era Low Jobless Claims

Amyris

The Dow Jones dropped around 145 points or 0.4%, the S&P 500 fell 0.4%, and the Nasdaq dipped 0.5%. Find opportunities in today's market with today's best short plays from Q.ai's artificial intelligence.

Amyris Inc Among Today's Top Shorts As Major Indices Fall Following The Fed's Meeting Minutes

Tupperware

Markets were in the red this morning by just shy of 1% across the board. Find opportunities in today's market with the best short plays from Q.ai's deep learning algorithms.

Carvana Co Ranked Among Today's Top Shorts

Markets were slightly lower this morning after the Dow Jones touched all-time highs at the open. Find opportunities in today's market with the best short plays from Q.ai's deep learning algorithms.

Arvinas Inc Ranked Among Today's Top Shorts

HONG KONG, Aug. 9, 2021 /PRNewswire/ -- Insilico Medicine is proud to announce an R&D collaboration with Arvinas (NASDAQ: ARVN). This strategic partnership will involve Insilico Medicine's AI-augmented platforms and close cooperation between Arvinas' and Insilico Medicine's scientists on novel PROTACs.

Insilico Medicine Announces an AI-driven PROTAC R&D Collaboration with Arvinas

ARVN is a pioneering protein degrader biopharma with strong early data. Recently, Pfizer inked a $2bn deal with the company for just one of its assets.

Arvinas: Tremendous Value Increase With Pfizer Mega-Deal, High Potential

Arvinas, Inc. (ARVN) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Recent Price Trend in Arvinas, Inc. (ARVN) is Your Friend, Here's Why

Arvinas, Inc. (ARVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Arvinas, Inc. (ARVN) to Report a Decline in Earnings: What to Look Out for

Arvinas, Inc. (ARVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Arvinas, Inc. (ARVN) Rating Upgrade to Buy

Arvinas, Inc. (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Arvinas, Inc. (ARVN) Moves 13% Higher: Will This Strength Last?

Pfizer

Arvinas (ARVN) collaborates with Pfizer for its investigational breast cancer candidate, ARV-471. Pfizer is also set to acquire an equity stake in Arvinas.

Arvinas (ARVN), Pfizer Team up for Breast Cancer Therapy

The smaller biopharma outfit just inked an encouraging deal with an industry powerhouse.

Why Arvinas Jumped 10% Today

The stock price of Arvinas Inc (NASDAQ: ARVN) increased by over 16% during intraday trading. This is why it happened.

ARVN Stock Increased Over 16% Intraday: Why It Happened

Arvinas Inc (NASDAQ: ARVN) and Pfizer Inc (NYSE: PFE) have collaborated to develop and commercialize ARV-471, an investigational oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor protein degrader.  The estrogen receptor is a well-known disease driver in most breast cancers.

Arvinas, Pfizer Announce $2.4B Licensing Agreement For Protein-Degrader Based Breast Cancer Therapy

Shares of Arvinas Inc. were up 6.0% in premarket trading on Thursday after the company announced a billion-dollar deal with Pfizer Inc. to develop and commercialize its experimental breast-cancer treatment. Pfizer will make a $650 million upfront payment to Arvinas, in addition to a $350 million equity investment.

Pfizer to pay at least $1 billion to develop, commercialize Arvinas' investigational breast-cancer therapy

– Collaboration combines Arvinas' investigational estrogen receptor-targeting breast cancer therapy with Pfizer's deep experience in breast oncology therapeutics –

Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein Degrader ARV-471

Annovis Bio

Anavex Life Sciences

Virtus LifeSci Biotech Clinical Trials ETF

VanEck Vectors Biotech ETF

Virtus LifeSci Biotech Products ETF

Biohaven Pharmaceutical Hld

Biogen

Loncar Cancer Immunotherapy ETF

Denali Therapeutics

First Trust NYSE Arca Biotechnology Index Fund

Amplify Treatments Testing & Advancements ETF

Global X Genomics & Biotechnology ETF

abrdn Life Sciences Investors 

iShares Nasdaq Biotechnology ETF

Defiance Nasdaq Junior Biotechnology ETF

INmune Bio Inc

Intra-Cellular Therapies

Karuna Therapeutics Inc

Direxion Daily S&P Biotech Bear 3X Shares

Direxion Daily S&P Biotech Bull 3X Shares

Eli Lilly

Invesco Dynamic Biotechnology & Genome ETF

Prothena

Cassava Sciences Inc

Supernus Pharmaceuticals

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

Biotechs are ready to march forcefully higher after a lengthy consolidation. Approval of Biogen's Alzheimer's treatment creates a bonanza for neurodegenerative-focused companies and the overall biotech sector.

Biotechs Ready To Roar

NEW HAVEN, Conn., June 07, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today joined state and local officials, fellow tenants, and community partners, in a groundbreaking ceremony for 101 College Street, a new 525,000-square-foot-building to be constructed as part of New Haven's Downtown Crossing revitalization project. Arvinas will lease three of the 10 floors at 101 College and this space will serve as the Company's headquarters beginning in 2024.

Arvinas Participates in Groundbreaking Ceremony for New Space Within Downtown Crossing Development in New Haven

Avadel Pharma

Neurocrine Biosciences

SAGE Therapeutics

Healthcare faces an important decision as the Supreme Court decides on the Affordable Care Act. Biotechs face an important FDA decision on approval of an Alzheimer's treatment.

Healthcare And Biotech Stocks Face Important Decisions, Remain A Promising Investment

Arvinas went public at $16 on September 26, 2018. The stock zoomed to $92.77 on the early trial successes of its two oncology targets. and currently trades at $67.18.

Connecting The Dots: Are Pfizer And Arvinas At Work On A COVID Cure?

NEW HAVEN, Conn., May 20, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Houston, Ph.D., President and Chief Executive Officer and Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the UBS Global Healthcare Virtual Conference on Tuesday, May 25 at 10:00 a.m. ET.

Arvinas to Present at the UBS Global Healthcare Virtual Conference

CEVA

eHealth

Hexcel

Workhorse Group

The Dow Jones climbed 220 points, the S&P 500 gained 0.8%, and the Nasdaq recovered another 1%. If you're looking for a way to play this market, the deep learning algorithms at Q.ai have crunched the data to find today's top shorts.

Arvinas Among Top Shorts Today As Dow, S&P 500, And Nasdaq Climb For Another Consecutive Day

– Company to lease approximately 160,000-square-feet to allow continued growth and expansion of operations – – Company to lease approximately 160,000-square-feet to allow continued growth and expansion of operations –

Arvinas Signs Lease for New Space Within Downtown Crossing Development in New Haven

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -7.69% and 41.37%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Arvinas, Inc. (ARVN) Reports Q1 Loss, Tops Revenue Estimates

News for Arvinas Inc Stock (ARVN)